Bicycle Therapeutics has started dosing of patients in a Phase I/IIa trial designed to examine BT1718 to treat patients with advanced solid tumours.

The trial expects to enrol 120 patients and will study the safety and preliminary efficacy of BT1718 in patients with high expression of membrane type 1 (MT1) tumour, as measured by a proprietary MT1 immunochemistry assay.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

After completing a rapid dose escalation phase, the trial is expected to evaluate two schedules of BT1718.

Bicycle Therapeutics chief medical officer Maria Koehler said: “BT1718 is the first clinical candidate from our pipeline of Bicycles, a brand-new class of chemically synthesised medicines.

“We believe that Bicycles, because of their small size and exquisite selectivity, could provide meaningful efficacy to patients suffering from cancer and avoid the toxicities associated with other classes of highly potent anti-cancer drugs.”

“We believe that Bicycles could provide meaningful efficacy to patients suffering from cancer and avoid the toxicities associated with other classes of highly potent anti-cancer drugs.”

Bicycle Therapeutics and Cancer Research UK are co-managing the Phase I/IIa trial.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

As part of the agreement, Bicycle retains the right to further advance the BT1718 programme, which undisclosed payment split between cash and equity, success-based milestones and royalty payments would be made to Cancer Research UK.

Cancer Research UK drug development director Dr Nigel Blackburn said: “We urgently need new, safe and effective therapies for patients with hard to treat cancers such as non-small cell lung cancer and triple negative breast cancer that this drug will tested on. Supporting this type of innovative clinical research is a key priority for Cancer Research UK.”

Cancer Research UK’s Centre for Drug Development (CDD) is sponsoring the trial.

BT1718 is a Bicycle Toxin Conjugate that targets membrane type 1 matrix metalloproteinase (MT1-MMP/MMP-14), which has been reported to be highly found in solid tumours.